神経内分泌腫瘍におけるLutatheraおよびASTX727 (LANTana)
転移性神経内分泌腫瘍患者におけるLutatheraによる治療結果を改善するためのソマトスタチン受容体-2のエピジェネティックな修飾。
Patients entered into the study will receive ASTX727 orally for 5 days, prior to receiving Lutathera treatment on Day 8, to determine whether pre-treatment with ASTX727 results in re-expression of somatostatin receptor-2 in patients with metastatic neuroendocrine tumours. The study will use [68Ga]-DOTA-TATE PET to image epigenetic modification of the receptor locus.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
Patients with neuroendocrine tumours (NET) who are found to be eligible will receive up to 4 doses of Lutathera on this trial. All participants will receive ASTX727 orally (cedazuridine 100mg + 35mg decitabine) Days 0-5 prior to receiving Lutathera Day 8 +/- 2days. Each cycle will be repeated every 2 months for 4 cycles unless unacceptable toxicity, progression of disease or withdrawal of patients' consent. Restaging will occur after 2 cycles of Lutathera and at the end of treatment. Patients will be followed 3 monthly until disease progression, death or withdrawal of patients' consent.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ 1
連絡先と場所
研究連絡先
研究連絡先
- 名前:Rohini Sharma, Professor
- 電話番号:02083833170
- メール:rohini.sharma2@nhs.net
研究場所
-
-
London, City of
-
London、London, City of、イギリス、W12 0HS
- 募集
- Hammersmith Hospital
-
コンタクト:
- Rohini Sharma, MD
- 電話番号:02075942807
- メール:rohini.sharma2@nhs.net
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Be willing and able to provide written informed consent for the trial.
-
Be aged 18 or over at the day of signing consent
-
Histologic or cytologic confirmed diagnosis of neuroendocrine tumour
-
Have archival tissue block available or willing to have fresh tissue biopsy if blocks not available
-
Have disease that can be readily biopsied by ultrasound guidance (n=5)
-
Ki67 < 55% (only patients with well differentiated grade 1-3 NETs will be included in the study as patients with poorly differentiated grade 3 NETs have a prognosis of less than 6 months)
-
Progression or intolerance to first line therapy including somatostatin analogues
-
ECOG Performance status 0 - 2
-
No tumoural uptake on [68Ga]-DOTA-TATE or uptake less than background liver
-
Measurable disease based on RECIST 1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions
-
Adequate organ function as outlined in the protocol
-
Women of childbearing potential must be willing to use a highly effective method of contraception as outlined in the protocol for the course of the study through 6 months after the last dose of Investigational Medicinal Product (IMP).
Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subjects
-
Sexually active males must agree to use an adequate method of contraception as outlined in the protocol starting with the first dose of IMP through 6 months after the last dose of study therapy. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject
Expansion Cohort (n=10 participants):
-
<50% disease occupation of liver
Exclusion Criteria:
- Previous treatment with either study medication and/or known hypersensitivity to the study medication
- Serious concurrent medical illness, including serious active infection
- History of organ transplant
- Has a known history of Human Immunodeficiency Virus (HIV). Note: No HIV testing is required unless mandated by local health authority.
- Has a known history of active Bacillus Tuberculosis (TB).
- Has known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e. without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.
- Bleeding or thrombotic disorders or subjects at risk for severe haemorrhage
- Is currently participating and receiving therapy or has participated or is participating in a study of an IMP or used an investigational device within 4 weeks of the first dose of IMP.
- Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
- Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating Principal Investigator (PI).
- Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
- Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through to 6 months after the last dose of IMP.
- Has received a live vaccine within 30 days of first dose of ASTX727 administration. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.
- Has received prior radiotherapy within 2 weeks of start of study treatment. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease and stereotactic radiotherapy to the CNS
- Other clinically significant co-morbidities that could compromise the subject's participating in the study
Expansion Cohort (n=10 participants):
15. > 2 lines of previous therapy, excluding somatostatin analogues
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:処理
|
Cedazuridine 100mg + 35mg decitabine Peptide receptor radionuclide therapy (PRRT)
他の名前:
|
|
他の:Expansion Cohort
|
Cedazuridine 100mg + 35mg decitabine Peptide receptor radionuclide therapy (PRRT)
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
To determine whether pre-treatment with ASTX727 results in re-expression of SSTR2 in patients with metastatic NETs, using [68Ga]-DOTA-TATE to image epigenetic modification of the SSTR2 locus allowing subsequent treatment with Lutathera
時間枠:Through study completion, an average of 1 year
|
This outcome will be assessed using a specific PET scan |
Through study completion, an average of 1 year
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
To assess tolerability of combination therapy
時間枠:Through study completion, an average of 1 year
|
This outcome will be assessed using CTCAE v5.0 |
Through study completion, an average of 1 year
|
|
To assess response to treatment using conventional imaging
時間枠:Through study completion, an average of 1 year
|
This outcome will be assessed using standard of care CT scans |
Through study completion, an average of 1 year
|
|
To assess patients quality of life during treatment
時間枠:Through study completion, an average of 1 year
|
This will be assessed using standardised quality of life questionnaires, which will be given to the patients |
Through study completion, an average of 1 year
|
|
To assess progression free survival
時間枠:Through study completion, an average of 1 year
|
This will be the time until patients show progressive disease on their routine CT scans |
Through study completion, an average of 1 year
|
協力者と研究者
協力者
協力者
捜査官
捜査官
- 主任研究者:Rohini Sharma, Professor、Imperial College London
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- RS - IC03
- 21HH6544 (その他の識別子:Imperial College London)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。